<p>Editas Medicine, Inc.（納斯達克代碼：EDIT - 獲取免費報告）首席執行官 Gilmore Neil O'neill 於 12 月 3 日星期三出售了 5,603 股公司股票，交易價格為每股平均 2.15 美元，總交易額為 12,046.45 美元。出售完成後，首席執行官直接持有公司 269,087 股股票，價值 578,537.05 美元。這代表其持股比例減少了 2.04%。該交易已在證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。</p>
<p>獲取 <strong>Editas Medicine</strong> 的提醒：</p>
<h2>Editas Medicine 股票上漲 2.5%</h2>
<ul>
<li>2 只基因編輯股票正在重塑遺傳疾病治療</li>
</ul>
<p>在週四的午盤交易中，納斯達克：EDIT 上漲 0.06 美元，達到 2.43 美元。該公司的交易量為 1,570,206 股，而其平均交易量為 2,730,958 股。該股票的 50 日移動平均價格為 3.12 美元，200 日移動平均價格為 2.70 美元。Editas Medicine, Inc.的 52 周最低價為 0.91 美元，52 周最高價為 4.54 美元。該公司的市值為 2.3722 億美元，市盈率為-1.02，貝塔值為 2.44。</p>
<p>Editas Medicine（納斯達克：EDIT - 獲取免費報告）最近一次發佈季度財報是在 11 月 10 日星期一。該公司報告季度每股收益（EPS）為-0.28 美元，超出分析師一致預期的-0.38 美元，超出幅度為 0.10 美元。該季度的收入為 754 萬美元，而分析師預期為 495 萬美元。Editas Medicine 的股本回報率為-277.29%，淨利潤率為-430.84%。作為一個整體，研究分析師預測 Editas Medicine, Inc.在本年度的每股收益將為-2.71 美元。</p>
<h2>分析師評級上調與下調</h2>
<ul>
<li>基因治療股票會成為市場下一個大贏家嗎？</li>
</ul>
<p>一些券商最近對 EDIT 發佈了報告。HC Wainwright 在 9 月 5 日星期五的研究報告中重申了 “買入” 評級，並將 Editas Medicine 的目標價設定為 5.00 美元。富國銀行在 9 月 3 日星期三的研究報告中將 Editas Medicine 的目標價從 3.00 美元上調至 4.00 美元，並給予該公司 “持平” 評級。Chardan Capital 在 11 月 13 日星期四的研究報告中將 Editas Medicine 的評級從 “持有” 上調至 “強力買入”。Wall Street Zen 在 9 月 26 日星期五的研究報告中將 Editas Medicine 的評級從 “賣出” 上調至 “持有”。最後，Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 Editas Medicine 的 “賣出（e+）” 評級。有兩位投資分析師給予該股票 “強力買入” 評級，三位給予 “買入” 評級，五位給予 “持有” 評級，二位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，平均目標價為 4.29 美元。</p>
<p><strong>查看我們最新的 EDIT 股票分析</strong></p>
<h2>Editas Medicine 的機構交易</h2>
<p>一些對沖基金和其他機構投資者最近買入和賣出了該股票的股份。CIBC Bancorp USA Inc.在第三季度購買了 Editas Medicine 的新股份，價值約 57,000 美元。Jacobs Levy Equity Management Inc.在第三季度將其在 Editas Medicine 的持股增加了 761.7%。Jacobs Levy Equity Management Inc.現在擁有 800,023 股公司股票，價值 2,776,000 美元，此前在上個季度又購買了 707,181 股。加拿大人壽保險公司在第三季度將其在 Editas Medicine 的股份增加了 43.3%。加拿大人壽保險公司現在擁有 45,754 股公司股票，價值 161,000 美元，此前在上個季度又購買了 13,816 股。XTX Topco Ltd 在第三季度將其在 Editas Medicine 的股份增加了 95.7%。XTX Topco Ltd 現在擁有 260,113 股公司股票，價值 903,000 美元，此前在上個季度又購買了 127,176 股。最後，俄亥俄州公共僱員退休系統在第三季度購買了 Editas Medicine 的新股份，價值約 262,000 美元。對沖基金和其他機構投資者持有該公司 71.90% 的股份。</p>
<h2>關於 Editas Medicine</h2>
<p>（獲取免費報告）</p>
<p>Editas Medicine, Inc.是一家臨牀階段的基因組編輯公司，專注於開發變革性的基因治療藥物，以治療一系列嚴重疾病。它開發了一種基於 CRISPR 技術的專有基因編輯平台。該公司正在開發 EDIT-101，目前正在進行 Leber 先天性黑朦的 1/2 期 BRILLIANCE 試驗；以及 reni-cel，一種用於治療鐮狀細胞病和輸血依賴性β-地中海貧血的臨牀開發基因編輯藥物。</p>
<h2>推薦故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Editas Medicine</li>
<li>複利是如何計算的？</li>
<li>利用 2026 年人工智能基礎設施收益的高增長 ETF</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>強勁的季度，疲軟的反應：為什麼 GitLab 的股票下跌</li>
<li>股息支付比率計算器</li>
<li>特斯拉開始 12 月的三個跡象</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RURJVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RURJVA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Editas Medicine 嗎？</h2>
<p>在考慮 Editas Medicine 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Editas Medicine 並不在名單上。</p>
<p>雖然 Editas Medicine 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

EDIT

<p>Editas Medicine 首席執行官 Gilmore Neil O'neill 出售了 5,603 股，交易金額為 12,046.45 美元，減少了 2.04% 的持股比例。出售後，他持有 269,087 股，價值 578,537.05 美元。該交易已在 SEC 文件中披露。Editas 股票上漲 2.5%，報 2.43 美元，市值為 2.3722 億美元。分析師的評級不一，平均目標價為 4.29 美元。機構投資者持有 71.90% 的股份</p>

<p>Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the firm's stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $2.15, for a total transaction of $12,046.45. Following the completion of the sale, the chief executive officer directly owned 269,087 shares in the company, valued at $578,537.05. This represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link.</p>
<div class="lb-trans"><p>Editas Medicine, Inc.（納斯達克代碼：EDIT - 獲取免費報告）首席執行官 Gilmore Neil O'neill 於 12 月 3 日星期三出售了 5,603 股公司股票，交易價格為每股平均 2.15 美元，總交易額為 12,046.45 美元。出售完成後，首席執行官直接持有公司 269,087 股股票，價值 578,537.05 美元。這代表其持股比例減少了 2.04%。該交易已在證券交易委員會的備案中披露，相關信息可通過此鏈接獲取。</p>
</div><p>Get <strong>Editas Medicine</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Editas Medicine</strong> 的提醒：</p>
</div><h2>Editas Medicine Stock Up 2.5%</h2>
<div class="lb-trans"><h2>Editas Medicine 股票上漲 2.5%</h2>
</div><ul>
<li>2 gene-editing stocks reshaping hereditary disease treatments</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因編輯股票正在重塑遺傳疾病治療</li>
</ul>
</div><p>NASDAQ:EDIT traded up $0.06 during midday trading on Thursday, hitting $2.43. The company had a trading volume of 1,570,206 shares, compared to its average volume of 2,730,958. The stock's fifty day moving average price is $3.12 and its 200-day moving average price is $2.70. Editas Medicine, Inc. has a 52-week low of $0.91 and a 52-week high of $4.54. The company has a market capitalization of $237.22 million, a PE ratio of -1.02 and a beta of 2.44.</p>
<div class="lb-trans"><p>在週四的午盤交易中，納斯達克：EDIT 上漲 0.06 美元，達到 2.43 美元。該公司的交易量為 1,570,206 股，而其平均交易量為 2,730,958 股。該股票的 50 日移動平均價格為 3.12 美元，200 日移動平均價格為 2.70 美元。Editas Medicine, Inc.的 52 周最低價為 0.91 美元，52 周最高價為 4.54 美元。該公司的市值為 2.3722 億美元，市盈率為-1.02，貝塔值為 2.44。</p>
</div><p>Editas Medicine (NASDAQ:EDIT - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.10. The firm had revenue of $7.54 million during the quarter, compared to analysts' expectations of $4.95 million. Editas Medicine had a negative return on equity of 277.29% and a negative net margin of 430.84%. As a group, research analysts forecast that Editas Medicine, Inc. will post -2.71 earnings per share for the current year.</p>
<div class="lb-trans"><p>Editas Medicine（納斯達克：EDIT - 獲取免費報告）最近一次發佈季度財報是在 11 月 10 日星期一。該公司報告季度每股收益（EPS）為-0.28 美元，超出分析師一致預期的-0.38 美元，超出幅度為 0.10 美元。該季度的收入為 754 萬美元，而分析師預期為 495 萬美元。Editas Medicine 的股本回報率為-277.29%，淨利潤率為-430.84%。作為一個整體，研究分析師預測 Editas Medicine, Inc.在本年度的每股收益將為-2.71 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調與下調</h2>
</div><ul>
<li>Are Gene Therapy Stocks The Market's Next Big Winners?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因治療股票會成為市場下一個大贏家嗎？</li>
</ul>
</div><p>A number of brokerages have recently issued reports on EDIT. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $5.00 price objective on shares of Editas Medicine in a research note on Friday, September 5th. Wells Fargo &amp; Company lifted their price objective on Editas Medicine from $3.00 to $4.00 and gave the company an &#34;equal weight&#34; rating in a research report on Wednesday, September 3rd. Chardan Capital upgraded shares of Editas Medicine from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Thursday, November 13th. Wall Street Zen upgraded Editas Medicine from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Friday, September 26th. Finally, Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Editas Medicine in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of &#34;Hold&#34; and an average target price of $4.29.</p>
<div class="lb-trans"><p>一些券商最近對 EDIT 發佈了報告。HC Wainwright 在 9 月 5 日星期五的研究報告中重申了 “買入” 評級，並將 Editas Medicine 的目標價設定為 5.00 美元。富國銀行在 9 月 3 日星期三的研究報告中將 Editas Medicine 的目標價從 3.00 美元上調至 4.00 美元，並給予該公司 “持平” 評級。Chardan Capital 在 11 月 13 日星期四的研究報告中將 Editas Medicine 的評級從 “持有” 上調至 “強力買入”。Wall Street Zen 在 9 月 26 日星期五的研究報告中將 Editas Medicine 的評級從 “賣出” 上調至 “持有”。最後，Weiss Ratings 在 10 月 8 日星期三的報告中重申了對 Editas Medicine 的 “賣出（e+）” 評級。有兩位投資分析師給予該股票 “強力買入” 評級，三位給予 “買入” 評級，五位給予 “持有” 評級，二位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，平均目標價為 4.29 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on EDIT</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 EDIT 股票分析</strong></p>
</div><h2>Institutional Trading of Editas Medicine</h2>
<div class="lb-trans"><h2>Editas Medicine 的機構交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CIBC Bancorp USA Inc. bought a new stake in Editas Medicine during the 3rd quarter worth approximately $57,000. Jacobs Levy Equity Management Inc. grew its holdings in Editas Medicine by 761.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 800,023 shares of the company's stock valued at $2,776,000 after buying an additional 707,181 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its stake in Editas Medicine by 43.3% during the third quarter. CANADA LIFE ASSURANCE Co now owns 45,754 shares of the company's stock valued at $161,000 after purchasing an additional 13,816 shares in the last quarter. XTX Topco Ltd raised its position in shares of Editas Medicine by 95.7% during the 3rd quarter. XTX Topco Ltd now owns 260,113 shares of the company's stock valued at $903,000 after buying an additional 127,176 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Editas Medicine in the 3rd quarter valued at approximately $262,000. Hedge funds and other institutional investors own 71.90% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近買入和賣出了該股票的股份。CIBC Bancorp USA Inc.在第三季度購買了 Editas Medicine 的新股份，價值約 57,000 美元。Jacobs Levy Equity Management Inc.在第三季度將其在 Editas Medicine 的持股增加了 761.7%。Jacobs Levy Equity Management Inc.現在擁有 800,023 股公司股票，價值 2,776,000 美元，此前在上個季度又購買了 707,181 股。加拿大人壽保險公司在第三季度將其在 Editas Medicine 的股份增加了 43.3%。加拿大人壽保險公司現在擁有 45,754 股公司股票，價值 161,000 美元，此前在上個季度又購買了 13,816 股。XTX Topco Ltd 在第三季度將其在 Editas Medicine 的股份增加了 95.7%。XTX Topco Ltd 現在擁有 260,113 股公司股票，價值 903,000 美元，此前在上個季度又購買了 127,176 股。最後，俄亥俄州公共僱員退休系統在第三季度購買了 Editas Medicine 的新股份，價值約 262,000 美元。對沖基金和其他機構投資者持有該公司 71.90% 的股份。</p>
</div><h2>About Editas Medicine</h2>
<div class="lb-trans"><h2>關於 Editas Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.</p>
<div class="lb-trans"><p>Editas Medicine, Inc.是一家臨牀階段的基因組編輯公司，專注於開發變革性的基因治療藥物，以治療一系列嚴重疾病。它開發了一種基於 CRISPR 技術的專有基因編輯平台。該公司正在開發 EDIT-101，目前正在進行 Leber 先天性黑朦的 1/2 期 BRILLIANCE 試驗；以及 reni-cel，一種用於治療鐮狀細胞病和輸血依賴性β-地中海貧血的臨牀開發基因編輯藥物。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦故事</h2>
</div><ul>
<li>Five stocks we like better than Editas Medicine</li>
<li>How is Compound Interest Calculated?</li>
<li>Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>Strong Quarter, Weak Reaction: Why GitLab Shares Dropped</li>
<li>Dividend Payout Ratio Calculator</li>
<li>3 Signs Tesla Is Starting December on the Front Foot</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Editas Medicine</li>
<li>複利是如何計算的？</li>
<li>利用 2026 年人工智能基礎設施收益的高增長 ETF</li>
<li>使用 MarketBeat 股息收益計算器</li>
<li>強勁的季度，疲軟的反應：為什麼 GitLab 的股票下跌</li>
<li>股息支付比率計算器</li>
<li>特斯拉開始 12 月的三個跡象</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RURJVA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=EDIT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Editas Medicine Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Editas Medicine 嗎？</h2>
</div><p>Before you consider Editas Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Editas Medicine 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Editas Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Editas Medicine 並不在名單上。</p>
</div><p>While Editas Medicine currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Editas Medicine 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Editas Medicine（NASDAQ:EDIT）的首席執行官出售了價值 12,046.45 美元的股票